Triple-action drug retatrutide delivers major weight loss for people with diabetes, Phase III trial finds

A caller Phase III objective trial, TRIUMPH-2, evaluated the efficacy and information of retatrutide, a triple receptor agonist and experimental once-weekly injection being developed to dainty obesity and benignant 2 diabetes. What sets it isolated from drugs specified arsenic semaglutide (Wegovy), which targets 1 hormone, and tirzepatide (Zepbound), which targets two, is its quality to activate 3 hormone receptors astatine once.